Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06034470CT.gov Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT05521204CT.gov Olverembatinib for FGFR1-rearranged Neoplasms | — | Recruiting | — | — | — |
NCT04250051CT.gov Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03589729CT.gov Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | — | Recruiting | — | — | — |
NCT02728050CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02521493CT.gov Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | — | Active Not Recruiting | — | — | — |
NCT02029950CT.gov Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02084563CT.gov Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | — | Completed | — | — | — |
NCT01101880CT.gov Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | — | Completed | — | — | — |
NCT00578539CT.gov T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT00080925CT.gov T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT00003619CT.gov Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | Fred Hutchinson Cancer Center | P3 | BB · 66 |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2/3 | BBB |
| Fludarabine | Sawa Ito, MD | P4 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2/3 | BB |
| Nivestim | City of Hope Medical Center | P3 | BB |
| Romidepsin | Sawa Ito, MD | P4 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2/3 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
+42 more in the Myeloproliferative Neoplasm cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytarabine in Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-myeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →